MDGL Madrigal Pharmaceuticals Inc

Price (delayed)

$251.63

Market cap

$5.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$19.99

Enterprise value

$5.02B

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum ...

Highlights
The company's quick ratio has surged by 130% QoQ and by 73% YoY
The equity has soared by 105% year-on-year
The debt has surged by 135% year-on-year
The company's net income fell by 27% YoY and by 8% QoQ

Key stats

What are the main financial stats of MDGL
Market
Shares outstanding
19.9M
Market cap
$5.01B
Enterprise value
$5.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$360.92M
EBITDA
-$360.39M
Free cash flow
-$325.71M
Per share
EPS
-$19.99
Free cash flow per share
-$17.43
Book value per share
$20.53
Revenue per share
$0
TBVPS
$34.28
Balance sheet
Total assets
$640.55M
Total liabilities
$235.21M
Debt
$117.19M
Equity
$405.33M
Working capital
$518.73M
Liquidity
Debt to equity
0.29
Current ratio
5.38
Quick ratio
5.35
Net debt/EBITDA
-0.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-98.8%
Return on equity
-219.4%
Return on invested capital
-124.2%
Return on capital employed
-69.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MDGL stock price

How has the Madrigal Pharmaceuticals stock price performed over time
Intraday
6.53%
1 week
6.38%
1 month
13.23%
1 year
-9.87%
YTD
8.75%
QTD
8.75%

Financial performance

How have Madrigal Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$380.5M
Net income
-$373.63M
Gross margin
N/A
Net margin
N/A
MDGL's operating income is down by 30% YoY and by 9% QoQ
The company's net income fell by 27% YoY and by 8% QoQ

Growth

What is Madrigal Pharmaceuticals's growth rate over time

Valuation

What is Madrigal Pharmaceuticals stock price valuation
P/E
N/A
P/B
12.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 16% YoY and by 3.9% from the previous quarter
The equity has soared by 105% year-on-year
The stock's price to book (P/B) is 76% less than its last 4 quarters average of 50.7 and 42% less than its 5-year quarterly average of 21.0

Efficiency

How efficient is Madrigal Pharmaceuticals business performance
Madrigal Pharmaceuticals's ROIC has soared by 74% YoY and by 46% from the previous quarter
The ROE has grown by 25% from the previous quarter and by 19% YoY
MDGL's return on assets is up by 20% year-on-year and by 12% since the previous quarter

Dividends

What is MDGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MDGL.

Financial health

How did Madrigal Pharmaceuticals financials performed over time
Madrigal Pharmaceuticals's total assets is 172% more than its total liabilities
Madrigal Pharmaceuticals's total assets has soared by 169% from the previous quarter and by 77% YoY
The company's quick ratio has surged by 130% QoQ and by 73% YoY
The debt is 71% smaller than the equity
The debt has surged by 135% year-on-year
The equity has soared by 105% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.